MAPT and tauopathy: At 6 months of age, mice injected with human mutant P301L tau-AAV recapitulate several behavioral and neuropathological hallmarks of tauopathy, including the accumulation of hyperphosphorylated and abnormally folded, protease-resistant tau species (13).